



March 29, 2017

## **Akebia to Present at the 16th Annual Needham Healthcare Conference**

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Akebia Therapeutics, Inc.](http://www.akebia.com) (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 16<sup>th</sup> Annual Needham Healthcare Conference on Tuesday, April 4, 2017, at 10:00 a.m. Eastern Time. The conference is being held at the Westin NY Grand Central Hotel in New York City.

A live audio webcast of the presentation will be available on the company's website at <http://ir.akebia.com/events.cfm>. Archived presentations will be available for 90 days.

### **About Akebia Therapeutics**

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia's lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia's global Phase 3 program for vadadustat, which includes the PRO<sub>2</sub>TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and the INNO<sub>2</sub>VATE studies for dialysis-dependent patients, is currently ongoing. For more information, please visit our website at [www.akebia.com](http://www.akebia.com).

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170329006005/en/>

### **Akebia**

Theresa McNeely, 617-844-6113  
SVP, Corporate Communications  
and Investor Relations  
[tmcneely@akebia.com](mailto:tmcneely@akebia.com)

Source: Akebia Therapeutics, Inc.

News Provided by Acquire Media